


<b>INDIAN INCOME TAX RETURN ACKNOWLEDGEMENT</b>				Assessment Year 2025-26
[Where the data of the Return of Income in Form ITR-1(SAHA)], ITR-2, ITR-3, ITR-4(SUGAM), ITR-5, ITR-6, ITR-7 filed and verified] (Please see Rule 12 of the Income-tax Rules, 1962)				
PAN	AACCD2775Q			
Name	DR NRKBIOTECH PRIVATE LIMITED			
Address	H.NO.502, SURAKSHA SOVENIR, WHITE FIELDS, KOTHAGUDA , HITECH CITY HYDERABAD-32 , 36-Telangana, 91-INDIA, 500084			
Status	7-Private company	Form Number	ITR-6	
Filed u/s	139(1)-On or before due date	e-Filing Acknowledgement Number	329162661291025	
Taxable Income and Tax Details	Current Year business loss, if any	1	74,58,749	
	Total Income	1A	0	
	Book Profit under MAT, where applicable	2	0	
	Adjusted Total Income under AMT, where applicable	3	0	
	Net tax payable	4	0	
	Interest and Fee Payable	5	0	
	Total tax, interest and Fee payable	6	0	
	Taxes Paid	7	0	
(+) Tax Payable /(-) Refundable (6-7)	8	0		
Accreted Income and Tax Detail	Accreted Income as per section 115TD	9	0	
	Additional Tax payable u/s 115TD	10	0	
	Interest payable u/s 115TE	11	0	
	Additional Tax and interest payable	12	0	
	Tax and interest paid	13	0	
	(+) Tax Payable /(-) Refundable (12-13)	14	0	
This return has been digitally signed by <u>SOHAM MODI</u> in the capacity of <u>Managing Director</u> having PAN <u>ABMPM6725H</u> from IP address <u>183.82.4.159</u> on <u>29-Oct-2025 13:28:50</u> at <u>HYDERABAD</u> (Place) DSC SI.No & Issuer <u>3097367</u> & <u>541953218203CN=Capricorn Sub CA for Individual DSC 2022,OU=Certifying Authority,O=Capricorn Identity Services Pvt Ltd.,C=IN</u>				
System Generated Barcode/QR Code	 AACCD2775Q063291626612910250b19a4dbba4a483df611e9bc8c494063653f91da			
<b>DO NOT SEND THIS ACKNOWLEDGEMENT TO CPC, BENGALURU</b>				

**NAME OF ASSESSEE** : DR NRKBIOTECH PRIVATE LIMITED  
**PAN** : AACCD2775Q  
**OFFICE ADDRESS** : H.NO.502, SURAKSHA SOVENIR, WHITE FIELDS, KOTHAGUDA, HITECH CITY  
 HYDERABAD-32, TELANGANA-500084  
**STATUS** : PUB NOT INT (PRIVATE LTD) **ASSESSMENT YEAR** : 2025 - 2026  
**WARD NO** : WARD 17(1), HYDERABAD/ **FINANCIAL YEAR** : 2024 - 2025  
**D.O.I.** : 23/12/2004  
**EMAIL ADDRESS** : nnagapooja@gmail.com  
**NAME OF BANK** : STATE BANK OF INDIA  
**IFSC CODE** : SBIN0020458  
**ADDRESS** : JUBILEE HILLS, HYDERABAD  
**ACCOUNT NO.** : 62062629504  
**OPTED FOR TAXATION U/S** : YES  
 115BAA  
**RETURN** : ORIGINAL  
**IMPORT DATE** : AIS : 28-10-2025 08:08 AM TIS : 28-10-2025 08:02 AM 26AS :  
 28-10-2025 08:07 AM  
**COMPUTATION DATE** : 29-10-2025 01:25 PM

### COMPUTATION OF TOTAL INCOME

#### PROFITS AND GAINS FROM BUSINESS OR PROFESSION

0

#### DR NRK BIOTECH PVT LTD

PROFIT BEFORE TAX AS PER PROFIT AND LOSS ACCOUNT -93,30,426

ADD :

DEPRECIATION DISALLOWED	3,62,626	
DISALLOWED U/S 37	47,903	
DISALLOWED U/S 43B	19,64,209	23,74,738
		-69,55,688

LESS :

INTEREST ON INCOME TAX REFUND	2,143	
ALLOWED DEPRECIATION	5,03,061	-5,05,204
		-74,60,892

OUT OF LOSS OF RS. 74,60,892, UNABSORBED DEPRECIATION  
IS RS. 5,03,061 & BUSINESS LOSS IS RS. 69,57,831

#### INCOME FROM OTHER SOURCES

2,143

INTEREST ON INCOME TAX REFUND

2,143

TOTAL

2,143

#### INTER-HEAD ADJUSTMENT OF LOSSES U/S 71

BUSINESS LOSS SET OFF FROM INCOME FROM OTHER  
SOURCES

-2,143

#### CURRENT YEAR LOSSES CARRIED FORWARD

BUSINESS LOSS OF Rs. 69,55,688  
UNABSORBED DEPRECIATION OF Rs. 5,03,061

**GROSS TOTAL INCOME**

NIL

**TOTAL INCOME**

NIL

### COMPUTATION OF TAX ON TOTAL INCOME

**TAX ON RS. NIL**

NIL

**TAX PAYABLE**

NIL

Information regarding Turnover/Gross Receipt Reported for GST



GSTR No.	36AACCD2775Q1Z3
Amount of turnover/Gross receipt as per the GST return filed	19,41,472

#### FIXED ASSETS

Block	Rate	WDV as on 01/04/2024	Addition		Deduction	Total	Depreciation for the Year	WDV as on 31/03/2025
			More than 180 Days	Less than 180 Days				
			Rs.	Rs.	Rs.	Rs.	Rs.	Rs.
BUILDING	10.00%	42,73,861.00	0.00	0.00	0.00	42,73,861.00	4,27,386.00	38,46,475.00
MACHINERY AND PLANT	15.00%	4,56,604.00	0.00	0.00	0.00	4,56,604.00	68,491.00	3,88,113.00
MACHINERY AND PLANT	40.00%	17,959.00	0.00	0.00	0.00	17,959.00	7,184.00	10,775.00
<b>Total</b>		<b>47,48,424.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>47,48,424.00</b>	<b>5,03,061.00</b>	<b>42,45,363.00</b>

#### LOSSES TABLE

A.Y.	HEAD	LOSSES		
		BROUGHT FORWARD	SET-OFF	CARRIED FORWARD
2020-21	Ordinary Business	90,68,419	-	90,68,419
2021-22	Ordinary Business	40,76,139	-	40,76,139
2022-23	Ordinary Business	18,33,437	-	18,33,437
2022-23	Unabsorbed Depreciation	6,19,241	-	6,19,241
2023-24	Ordinary Business	46,69,612	-	46,69,612
2023-24	Unabsorbed Depreciation	6,57,407	-	6,57,407
2024-25	Ordinary Business	69,10,858	-	69,10,858
2024-25	Unabsorbed Depreciation	5,67,423	-	5,67,423
2025-26	Ordinary Business	-	-	69,55,688
2025-26	Unabsorbed Depreciation	-	-	5,03,061

#### ALLOWED/DISALLOWED U/S 43B

Particulars	Assessment Year	Disallowed Amount (Rs.)	Allowed Amount (Rs.)	Balance Amount (Rs.)
Amount Due To Mse	2025-26	19,64,209	-	19,64,209
<b>Total</b>		<b>19,64,209</b>	<b>-</b>	<b>19,64,209</b>

#### DISALLOWED U/S 37

Sr. No.	Particulars	Amount
1	Interest on TDS	47,903
	<b>Total</b>	<b>47,903.00</b>

#### Details of Share holders holding not less than 10% of the voting power at any time during P.Y.

Name	PAN	Percentage of share	Address
B ANAND KUMAR	AENPB5288E	10	37-18/869, JAI NIALAYAM PLC 869DEFENCE COLONY,STH AVENUE BAKER, SAINIKPURI POST MALKAJGIRI, HYDERABAD TELANGANA - 500094
K VENKATA NAGABHUSHNAM	GBQPK9941B	10	6-3-286/23RD CROSS ROAD, HASTINAPURI COLONY,SAINIKPURI, HYDERABAD TELANGANA - 500094
N VENKATA NARSIMHA MURTY	AHPPK9998K	10	PLOT NO.48,1ST FLOOR,SRIDHAMAM, SRI CHAKRA ENCLAVESAINIKPURI, HYDERABAD TELANGANA - 500094
K VIJAY BHASKAR	AHSPK3785B	10	JALAVAYU VIHAR COLONY, OPP KPHB COLONY,TIRUMALAGIRI,JNTU KUKATPALLY,

			HYDERABAD TELANGANA - 500085
MODI PROPERTIES PVT LTD	AABCM4761E	15	5-4-187/3&4, SOHAM MANSIONMAHATMA GANDHI ROAD, SECUNDERABAD, HYDERABAD TELANGANA - 500003
N KIRAN KUMAR	ABVPN1278M	10	5-11-233, PLOT NO 275 VENKATESHWARA NAGAR, NEAR MOTHER THERESA HISH SCHOOL, MEERPET, MOULALI, HYDERABAD TELANGANA - 500040
N KRISHNA VENI	AIZPN1755E	10	7-1-277/353-53C LIGH SANJEEV REDDY NAGAR COLONY, SR NAGAR AMEERPET, HYDERABAD TELANGANA - 500038
JVRX ASSET MANAGEMENT PRIVATE LIMITED	AAACJ1234A	15	Sy.No.403/1(Old), 120(New), 4th Floor, Niharika Jubilee One Road No.1, Jubilee Hills, Hyderabad TELANGANA - 500033
MODI HOUSING PRIVATE LIMITED	AAACM1234A	0	5-4-187/3 AND 4, 3RD FLOOR, SOHAM MANSIONM.G.ROAD, SECUNDERABAD, SECUNDERABAD TELANGANA - 500003
<b>Total</b>		<b>90.00</b>	

### Schedule-SH1 [SHAREHOLDING OF UNLISTED COMPANY]

#### 1. Details of shareholding at the end of the previous year

Sr. No.	Name of the shareholder	Resident ial status in India	Type of share	Others	PAN	AADHAAR	Date of allotment	Number of shares held	Face value per share	Issue Price per share	Amount received
1	B ANAND KUMAR	Resident	Equity Shares		AENPB5288E		24/06/2021	2,41,100	10	10	24,11,000
2	JVRX ASSET MANAGEMENT PVT LTD	Resident	Equity Shares		AAECU9813D		24/06/2021	3,61,650	15	10	36,16,500
3	K VENKATA NAGABHUSH NAM	Resident	Equity Shares		GBQPK9941B		24/06/2021	2,41,100	10	10	24,11,000
4	K VENKATA NARSIMHA MURTY	Resident	Equity Shares		AHPPK9998K		24/06/2021	2,41,100	10	10	24,11,000
5	K VIJAY BHASKAR	Resident	Equity Shares		AHSPK3785B		24/06/2021	2,41,100	10	10	24,11,000
6	MODI PROPERTIES PVT LTD	Resident	Equity Shares		AABCM4761E		24/06/2021	3,61,650	15	10	36,16,500
7	MODI HOUSING PVT LTD	Resident	Equity Shares		AADCM5906D		26/09/2024	2,41,100	10	10	24,11,000
8	N KIRAN KUMAR	Resident	Equity Shares		ABVPN1278M		24/06/2021	2,41,100	10	10	24,11,000
9	N KRISHNA VENI	Resident	Equity Shares		AIZPN1755E		24/06/2021	2,41,100	10	10	24,11,000
	<b>Total</b>							<b>24,11,000.00</b>			<b>2,41,10,000.00</b>

### Schedule-AL1 [Assets and liabilities as at the end of the year]

#### B. Details of land or building or both not being in the nature of residential house

Sr. No.	Address	Pin code	Date of acquisition	Cost of acquisition	Purpose for which used
1	PLOT NO 11, ADMEASURING 11 471 SQ. YARDS, IN SHAPOORJI PALLONJI BIO TECH PARK, PHA SE 1, HYDERABAD, RR DIST	500038	15/04/2005	1,58,42,501	Own Office
	<b>Total</b>			<b>1,58,42,501</b>	



**G. Details of Loans & Advances to any other concern (If money lending is not assessee's substantial business)**

Sr. No.	Name of the person	PAN	Opening balance	Amount received	Amount paid	Interest debited, if any	Closing balance	Rate of interest (%)
1	ADROIT TECHNICAL SERVICES PVT LTD	NOPAA1234A	1,94,700	0	0	0	1,94,700	0.00
2	HI TECH POWER ENTERPRISES	AIXPP4447K	7,17,000	10,00,000	0	0	2,83,000	0.00
3	MAA SAI SEATINGS	AJZPK4074G	1,750	0	0	0	1,750	0.00
4	MODI HOUSING PVT LTD-TRADING A/C.	AADCM5906D	3,45,348	23,54,158	10,44,847	0	9,63,963	0.00
5	PIRGALS HOUSE OF ELECTRONICS & HOMES APPLIANCES	ADYPP7519G	37,328	0	0	0	37,328	0.00
6	S A SPORTS	AAGFS2959C	84,000	0	0	0	84,000	0.00
7	SFS HARDWARE	BJJPG3515K	57,051	0	0	0	57,051	0.00
8	BANITA DAS	GHVPD1030H	27,517	0	0	0	27,517	0.00
9	MD. KHUDOOS	BLFPK1605L	1,602	50,000	0	0	51,602	0.00
10	E PRASAD	ABLPE7695K	0	2,400	0	0	2,400	0.00
11	MODI CONSTRUCTIONS & REALTORS LLP	ABJFM5257F	20,24,578	20,000	20,24,578	0	20,000	0.00
12	KULKARNI CONSULTANTS	ADOPR1855P	0	54,000	59,000	0	5,000	0.00
13	ARENA CONSULTANTS	AHZPS4818C	4,18,738	0	0	0	4,18,738	0.00
14	KORUKONDA BHATTAR SRIVATHSA	AERP5245B	1,25,000	0	0	0	1,25,000	0.00
15	MODI HOUSING PVT LTD-SERVICES	AADCM5906D	4,826	1,19,422	75,385	0	39,211	0.00
16	S V ELECTRICALS	AOAPK9950M	69,000	0	0	0	69,000	0.00
	<b>Total</b>		<b>41,08,438</b>	<b>35,99,980</b>	<b>32,03,810</b>	<b>0</b>	<b>23,80,260</b>	

**H. Details of motor vehicle, aircraft, yacht or other mode of transport**

Sr. No.	Particulars of asset	Others	Registration number of vehicle	Cost of acquisition	Date of acquisition	Purpose for which used
1	Others	MARUTI ALTO	TS08HV1024	4,39,693	25/10/2021	Own Business Use
	<b>Total</b>			<b>4,39,693</b>		

**I. Details of liabilities (Details of loans, deposits and advances taken from a person other than financial institution)**

Sr. No.	Name of the person	PAN	Opening balance	Amount received	Amount paid	Interest credited, if any	Closing balance	Rate of interest (%)
1	JVRX ASSET MANAGEMENT PVT. LTD. ICD	AAECJ9813D	25,00,000	0	0	0	25,00,000	0.00
2	ANAND KUMAR BHASHYAKARLA	AENPB5288E	2,31,25,000	0	40,00,000	0	2,71,25,000	0.00
3	JVRX ASSET MANAGEMENT PVT LTD - ICD	AAECJ9813D	66,51,056	0	0	0	66,51,056	0.00
4	KALLURI VENKATA NAGABHUSHANAM	GBQPK9941B	2,31,25,000	0	0	0	2,31,25,000	0.00
5	KALLURI VENKATA NARASIMHAMURTHY	AHPPK9998K	2,31,25,000	0	55,00,000	0	2,86,25,000	0.00

6	MODI HOUSING PVT LTD	AADCM590 6D	0	0	5,07,00,000	0	5,07,00,000	0.00
7	MODI PROPERTIES PVT LTD	AABCM476 1E	4,90,81,500	5,32,57,349	11,72,91,321	0	11,31,15,472	0.00
8	NAREDDY KIRAN KUMAR	ABVPN1278 M	2,31,25,000	0	50,00,000	0	2,81,25,000	0.00
9	NAREDLA KRISHNAVENI	AIZPN1755 E	1,76,25,000	10,00,000	0	0	1,66,25,000	0.00
10	VIJAYA BHASKAR REDDY	AKSPK3785 B	2,31,25,099	0	30,00,000	0	2,61,25,099	0.00
	<b>Total</b>		<b>19,14,82,655</b>	<b>5,42,57,349</b>	<b>18,54,91,321</b>	<b>0</b>	<b>32,27,16,627</b>	

#### Details of Turnover as per GSTR-3B (As per AIS)

Sr. No.	GSTIN	ARN	Date of filing	Return Period	Taxable Turnover	Total Turnover
1	36AACCD2775Q1Z3	126240003679894		APR-2024	0.00	0.00
2	36AACCD2775Q1Z3	126240183066893		JUN-2024	0.00	0.00
3	36AACCD2775Q1Z3	126240083942515		MAY-2024	5,19,558.97	5,19,558.97
4	36AACCD2775Q1Z3	126240286964913		AUG-2024	0.00	0.00
5	36AACCD2775Q1Z3	126240287659467		JUL-2024	8,42,688.06	8,42,688.06
6	36AACCD2775Q1Z3	126240574341234		SEP-2024	0.00	0.00
7	36AACCD2775Q1Z3	126240573867711		OCT-2024	1,12,500.00	1,12,500.00
8	36AACCD2775Q1Z3	126240671733567		NOV-2024	0.00	0.00
9	36AACCD2775Q1Z3	126240761232519		DEC-2024	0.00	0.00
10	36AACCD2775Q1Z3	126240973031529		MAR-2025	0.00	0.00
11	36AACCD2775Q1Z3	126240864989070		JAN-2025	51,464.00	51,464.00
12	36AACCD2775Q1Z3	126241074385927		FEB-2025	4,15,261.00	4,15,261.00
				<b>Total</b>	<b>19,41,472.03</b>	<b>19,41,472.03</b>

#### Details of Taxpayer Information Summary

S. N.	Information Category	Income Head	Section	Processed Value	Derived Value	As per Computation/ ITR	Difference	As per 26AS	Difference
	(1)	(2)	(3)	(4)	(5)	(6)	(7)=(5)-(6)	(8)	(9)=(8)-(6)
1	GST turnover	Profit & Loss A/c		19,41,472.00	19,41,472.00	19,41,472.00	Nil	0.00	-19,41,472.00
2	GST purchases	Profit & Loss A/c		1,58,58,497.00	1,58,58,497.00	0.00	1,58,58,497.00		

#### Nature of Business

##### OTHER THAN THOSE DECLARING INCOME UNDER SECTIONS 44AD/44ADA/44AE

SN	Business Code	Description	Trade Name
1	04041 - MANUFACTURING - Manufacture of pharmaceuticals, medicinal chemicals and botanical products	manufacturing pharmaceuticals, medicinal chemicals and botanical products.	DR. N.R.K. BIO-TECH PRIVATE LIMITED

**SOHAM MODI**  
(Managing Director)



## INDEPENDENT AUDITOR'S REPORT

To The Members of DR. N.R.K BIO-TECH PRIVATE LIMITED

### Report on Audit of the Financial Statements

#### Opinion

We have audited the accompanying financial statements of **DR. N.R.K BIO-TECH PRIVATE LIMITED** (the 'Company'), which comprise the balance sheet as at 31<sup>st</sup> March 2025, the statement of profit and loss for the year then ended and notes to the financial statements, including a summary of the significant accounting policies and other explanatory information (herein after referred to as "the financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India including Accounting Standards specified under Section 133 of the Act, of the state of affairs of the company as at 31<sup>st</sup> March 2025, its loss for the year ended on that date.

#### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements Section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Material Uncertainty Related to Going Concern

We draw attention to Note 4 in the financial statements, which indicates that the Company incurred a net loss of Rs. 92,845 (amount in hundreds) during the year ended March 31, 2025. The management is confident of commencing commercial operations by 31<sup>st</sup> December, 2025 and has secured necessary funding commitments from Promoters and Financers to meet the project completion costs and working capital requirements. As stated in Note 1-2 these events or conditions, along with other matters as set forth in Note 1-2, indicate that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

#### Responsibilities of Management for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act read with the Companies (Accounting Standards) Rules, 2021.



T: 040 2324 0700  
040 2324 0900



[www.Lncofirm.in](http://www.Lncofirm.in)



**Laxminiwas & Co.**

Head Office: 6-3-569, 4<sup>th</sup> Floor, Above BMW Showroom,  
Opp. RTA Office Khairatabad, Hyderabad 500082, Telangana, India.



The responsibility also includes maintenance of the adequate accounting records for safeguarding assets of the company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the management of the company is responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The management and Board of Directors are also responsible for overseeing the company's financial reporting process.

### **Auditor's Responsibility for Audit of Financial Statements:**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit.

We also:

1. Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are





required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the entity to cease to continue as a going concern.

5. Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Materiality is the magnitude of misstatement in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatement in the standalone financial statements.

We communicate with the Board of Directors, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the Board of Directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### **Report on Other Legal and Regulatory Requirements**

1. This report does not include a statement on the matters specified in Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, since in our opinion and according to the information and explanation given to us, the said Order is not applicable to the company.
2. Clause (i) of section 143 (3) is not applicable pursuant to notification G.S.R 583(E) dated 13 June 2017.
3. As required by Section 143 (3) of the Act, we report that:
  - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
  - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
  - (c) The Balance Sheet and the Statement of Profit and Loss dealt with by this report are in agreement with the books of account;
  - (d) In our opinion, the aforesaid financial statements comply with the Accounting standards specified under Section 133 of the Companies Act, 2013.



- (e) On the basis of the written representations received from the directors and taken on record by the Board of Directors, none of the directors is disqualified as on 31<sup>st</sup> March 2025 from being appointed as a director in terms of Section 164 (2) of the Act;
- (f) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- (i) There are no pending litigations on or by the company, the impact of which needs to be disclosed in financial statement.
  - (ii) The Company does not have any long-term contracts, including derivative contracts, for which there were any material foreseeable losses; and
  - (iii) There are no amounts which were required to be transferred to the Investor Education and Protection Fund during the year ended 31<sup>st</sup> March 2025.
  - (iv)
    - a. The management has represented that, to the best of it's knowledge and belief, other than as disclosed in the notes to the accounts, funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether,
      - a. directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or
      - b. provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
    - b. The management has represented, that, to the best of it's knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether,
      - a. directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or
      - b. provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
    - c. Based on our audit procedures, we have considered it reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause iv(a) and iv(b) contain any material misstatement.






- (v) The company has not declared or paid any dividend during the year.
- (g) With respect to the matter to be included in the Auditor's Report under section 197(16) of the Act, in our opinion, and according to the information and explanations given to us, and based on our examination of the records of the company, the provisions of section 197 read with Schedule V of the Act are not applicable to the Company as it a private limited company.
- (h) Based on our examination which included test check the company have used an accounting software for maintaining its books of account which has a feature of recording audit trail (Edit log) facility and the same has operated throughout the year for all relevant transaction recorded in the software. For the, during the course of our audit, we did not come across any instance in audit trail feature being tampered with. Additionally, the Audit trail has been preserved by the company as per the statutory requirements for record retention.

**For LAXMINIWAS & CO.**

Chartered Accountants


Firm's Registration Number: 011168S



**VIJAY SINGH**

Partner

Membership Number: 221671



Place: Hyderabad

Date: 02 September 2025

UDIN:25221671BMJBQK3345

**DR. N.R.K. BIO-TECH PRIVATE LIMITED**  
**BALANCE SHEET AS AT MARCH 31, 2025**


(All amounts in Rs. hundreds, unless otherwise stated)


Particulars	Notes	As at March 31st, 2025	As at March 31st, 2024
<b>Equity and Liabilities</b>			
<b>Shareholders' Funds</b>			
Share Capital	3	2,41,100	2,41,100
Reserves and Surplus	4	(4,18,519)	(2,95,359)
		<b>(1,77,419)</b>	<b>(54,259)</b>
<b>Non-Current Liabilities</b>			
Long-term Borrowings	5A	36,99,640	33,04,588
<b>Current Liabilities</b>			
Trade Payables	6	1,44,256	1,42,178
Short Term Borrowings	5B	625	76,050
Other Current Liabilities	7	1,96,046	50,578
Short Term Provision	8	369	369
<b>Total</b>		<b>38,63,517</b>	<b>35,19,504</b>
<b>Assets</b>			
<b>Non-Current Assets</b>			
Property, Plant & Equipment	9A	2,04,466	2,08,093
-Tangible Assets	9B	32,35,759	28,55,307
-Capital Work in Progress		<b>34,40,225</b>	<b>30,63,400</b>
Deferred Tax Asset (Net)	10	5,939	35,795
<b>Current Assets</b>			
Trade receivables	11	3,249	-
Cash and Cash Equivalents	12	4,032	8,613
Loans & Advances	13	4,10,071	1,14,815
Other Current Assets	14	-	2,96,880
<b>Total</b>		<b>38,63,517</b>	<b>35,19,504</b>

**Significant Accounting Policies and Notes to Accounts**  
The notes referred to above form an integral part of financial statements.

1 & 2


As per our report of even date  
for **Laxminiwas & Co.**  
**Chartered Accountants**  
Firm Registration No. 011168S

  
**Vijay Singh**  
Partner  
Membership No. 221671




Place : Hyderabad  
Date : 02 September 2025

For and on behalf of directors of  
**Dr. N.R.K. Bio-Tech Private Limited**  
CIN: U45100TG2004PTC044950

  
**Soham Satish Modi**  
Director  
DIN: 00522546



  
**Anand Kumar Bhashyakarla**  
Director  
DIN: 07739186



**DR. N.R.K. BIO-TECH PRIVATE LIMITED**  
**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2025**  
*(All amounts in Rs. hundreds, unless otherwise stated)*

Particulars	Notes	Year Ended March 31st, 2025	Year Ended March 31st, 2024
<b>Revenue</b>			
Revenue from Operations	15	-	-
Other Income	16	19,960	5,052
<b>Total income</b>		<b>19,960</b>	<b>5,052</b>
<b>Expenditure</b>			
Purchase of stock-in-trade			-
Change in Inventories of finished goods, work in process and stock in trade			-
Employee Benefit Expenses	17	25,971	7,350
Depreciation and Amortisation	8A & 8B	3,626	3,500
Finance Costs	18	7	28
Other Administrative Expenses	19	83,660	70,971
<b>Total expenses</b>		<b>1,13,264</b>	<b>81,850</b>
<b>Loss before tax</b>		<b>(93,304)</b>	<b>(76,798)</b>
<b>Tax Expense:</b>			
-Current Tax		(29,856)	49
-Income Tax relating to previous years		-	-
-Deferred Tax expense/(income)		(29,856)	49
<b>Loss for the year</b>		<b>(1,23,160)</b>	<b>(76,847)</b>
<b>Earnings Per Share (EPS)</b>			
Basic		(0.05)	(0.03)
Diluted		(0.05)	(0.04)

**Significant Accounting Policies and Notes to Accounts** 1 & 2  
The notes referred to above form an integral part of financial statements.

As per out report of even date  
for **Laxminiwas & Co.**

**Chartered Accountants**

Firm Registration No. 011168S

*Vijay Singh*

**Vijay Singh**  
Partner

Membership No. 221671



For and on behalf of directors of  
**Dr. N.R.K. Bio-Tech Private Limited**  
CIN: U45100TG2004PTC044950

*Soham Satish Modi*  
**Soham Satish Modi**  
Director  
DIN: 00522546



*Anand Kumar Bhashyakarla*  
**Anand Kumar Bhashyakarla**  
Director  
DIN: 07739186

Place : Hyderabad

Date : 02 September 2025

**DR. N.R.K. BIO-TECH PRIVATE LIMITED**  
**NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2025**  
(All amounts in Rs. hundreds, unless otherwise stated)

**1 CORPORATE INFORMATION**

Dr. N.R.K. Bio-Tech Private Limited ("The Company") is a private limited company domiciled in India and incorporated under the provisions of Companies Act, 2013. The Company was incorporated on 23rd December 2004 and the company is engaged in manufacturing pharmaceuticals, medicinal chemicals and botanical products. Its registered office and Principal place of business is situated at TSIC Industrial Development Area, Plot no.11, S no. 230 to 243, Turkapally, Medchal-Malkajgiri Dist, Hyderabad, Telangana, India, 500078

**2 SIGNIFICANT ACCOUNTING POLICIES**

**Basis of preparation:**

- The financial statements of the company have been prepared and presented under the historical cost convention, on the accrual and going concern basis of accounting in accordance with the accounting principles generally accepted in India ("Indian GAAP") and comply with the Accounting standards prescribed in the Companies (Accounting Standards) Rules, 2006 which continue to apply under Section 133 of the Companies Act, 2013 ("the Act") read with Rule 7 of the Companies (Accounts) Rules, 2014.
- All assets and liabilities have been classified as current or non-current as per the Company's operating cycle and other criteria set out in the Schedule III (Division-I) to the Companies Act, 2013. Based on the nature of products dealt with and services rendered and the time between the acquisition of assets for processing and their realization in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current - non-current classification of assets and liabilities.
- Rounding of amounts: All amount disclosed in these standalone financial statements and notes have been rounded off in Rs. Hundreds as per the requirement of Schedule III, unless otherwise stated.

**Basis of Accounting:**

These standalone financial statements have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) including the Accounting Standards notified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and the relevant provisions of the Companies Act, 2013.

**Use of Estimates:**

The preparation of financial statements in conformity with Indian GAAP requires judgments, estimates and assumptions to be made that affect the reported amount of assets and liabilities, disclosure of contingent liabilities on the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Difference between the actual results and estimates are recognized in the period in which the results are known/materialized.

**Current/ Non-Current Classification:**

All assets and liabilities have been classified as current or noncurrent as per the Company's normal operating cycle and other criteria set out in the Schedule III to the Companies Act, 2013. Based on the nature of products and the time between acquisition of assets for processing and their realization in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current/non-current classification of assets and liabilities.

**Revenue Recognition:**

Revenue is measured at fair value of the consideration received or receivable. The company recognises revenue when the amount of revenue can be reliably measured, it is probable that future economic benefit will flow to the company and specific criteria have been met for each of the companies activities.

Revenue from sale of services is recognised on transfer of all significant risks and rewards of ownership on completion of service. The amount recognised as revenue is exclusive of taxes

Interest income is recognised on the time proportion basis

**Cash and cash equivalents:**

Cash and cash equivalents include cash in hand, demand deposits with banks, other short-term highly liquid investments with original maturities of three months or less.

**Property Plant and Equipment and Intangible Assets**

**Tangible Assets:**

Tangible Assets, capital work in progress are stated at cost net of recoverable taxes, trade discounts and rebates and include amounts added on revaluation, less accumulated depreciation and impairment loss, if any. The cost of tangible assets comprises its purchase price, borrowing cost and any cost directly attributable to bringing the asset to its working condition for its intended use, net charges on foreign exchange contracts and adjustments arising from exchange rate variations attributable to the assets. Subsequent expenditures related to an item of tangible asset are added to its book value only if they increase the future benefits from the existing asset beyond its previously assessed standard of performance. Projects under which assets are not ready for their intended use are shown as Capital Work-in-Progress.

**Intangible Assets:**

An intangible asset is recognized when it is probable that the future economic benefits attributable to the asset will flow to the enterprise and where its cost can be reliably measured. Intangible Assets are stated at cost of acquisition net of recoverable taxes less accumulated amortization/depletion and impairment loss, if any. The cost comprises purchase price, borrowing costs, and any cost directly attributable to bringing the asset to its working condition for the intended use and net charges on foreign exchange contracts and adjustments arising from exchange rate variations attributable to the intangible assets. Subsequent expenditure relating to intangible assets is capitalized only if such expenditure results in an increase in the future benefits from such asset beyond its previously assessed standard of performance.

**Depreciation**

Depreciation on Property, Plant and equipment is provided on written down value method in accordance with the rates and in the manner provided in the schedule II to the Companies Act, 2013. Depreciation on addition to tangible assets is provided on pro-rata basis from the date the assets are ready for intended use.

Depreciation on sale/discard of tangible assets is provided for up-to the date of sale, deduction or discard of tangible assets as the case may be. The Company has adopted Schedule II to the Companies Act, 2013 which requires identification and determination of separate useful life for each major component of the property, plant and equipment, if they have useful life that is materially different from that of the remaining asset.

**Impairment**

The Company assesses at each balance sheet date whether there is any indication that an asset may be impaired. If any such indication exists, the company estimates the recoverable amount of the asset.

The recoverable amount of an asset is the greater of its value in use and its net selling price. If such recoverable amount of the assets is less than its carrying amount, the carrying amount is reduced to its recoverable amount. The reduction is treated as an impairment loss and is recognized in the statement of profit and loss. If at the balance sheet date there is an indication that a previously assessed impairment loss no longer exists, the recoverable amount is reassessed and the asset is reflected at the recoverable amount subject to a maximum of amortized historical cost.



AK

Handwritten signature



**DR. N.R.K. BIO-TECH PRIVATE LIMITED**  
**NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2025**

**Investments**

Investments that are readily realizable and are intended to be held for not more than one year from the date, on which such investments are made, are classified as current investments. All other investments are classified as long-term investments.

On initial recognition, all investments are measured at cost. The cost comprises purchase price and directly attributable acquisition charges such as brokerage, fees and duties. If an investment is acquired, or partly acquired, by the issue of shares or other securities, the acquisition cost is the fair value of the securities issued. If an investment is acquired in exchange for another asset, the acquisition is determined by reference to the fair value of the asset given up or by reference to the fair value of the investment acquired, whichever is more clearly evident.

Current investments are carried at cost or fair value, whichever is lower. Long-term investments are carried at cost. However, provision for diminution is made to recognize a decline, other than temporary, in the value of the investments. Such reduction if any is determined and made for each investment individually. On disposal of an investment, the difference between its carrying amount and net disposal proceeds is charged or credited to the Statement of Profit and Loss.

**Inventories**

Inventories are stated at lower of cost and net realizable value. However, these items are considered to be realizable at replacement cost if the finished goods, in which they will be used, are expected to be sold below cost. Cost includes purchase price, (excluding those subsequently recoverable by the enterprise from the concerned revenue authorities), freight inwards and other expenditure incurred in bringing such inventories to their present location and condition. Cost is determined on the weighted average basis. The cost of raw materials, stores and spares and other consumables comprises cost of material and includes all applicable costs incurred in bringing goods to their present location and condition.

Work in progress and manufactured finished goods are valued at the lower of cost and net realizable value. Cost of work in progress and manufactured finished goods is determined on the weighted average basis and comprises direct material, Cost of conversion and other costs incurred in bringing these inventories to their present location and condition. Cost of traded goods is determined on a weighted average basis.

Provision of obsolescence on inventories is considered on the basis of management's estimate based on demand and market of the inventories.

Net realizable value is the estimated selling price in the ordinary course of business, less the estimated cost of completion and the estimated costs necessary to make the sale. The comparison of cost and net realizable value is made on item by item basis.

**Borrowing costs**

Borrowing cost includes interest, amortization of ancillary costs incurred in connection with the arrangement of borrowings and exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost. Borrowing costs that are directly attributable to the acquisition, construction or production of an asset that takes a substantial period of time to get ready for its intended use or sale are capitalized until such time as the assets are substantially ready for their intended use or sale. All other borrowing costs are recognized as expenditure in the period in which they are incurred.

**Provisions, Contingent Liabilities and Contingent Assets**

Provision is recognized in the accounts when there is a present obligation as a result of past event(s) and it is probable that an outflow of resources will be required to settle the obligation and a reliable estimate can be made. Provisions are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the reporting date. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.

**Employee Benefits:**

**Defined Contribution Plan:**

Contribution as per Employee's Provident Funds and Miscellaneous Provisions Act, 1952 towards Provident Fund and Family Pension Fund are provided for and payments in respect thereof are made to the relevant authorities on actual basis.

**Taxation**

**Current Tax**

Tax expense comprises of current tax (i.e. amount of tax for the period is determined in accordance with the Income Tax Act, 1961) and deferred tax charge or credit (reflecting the tax effect of timing differences between accounting income and taxable income for the period)

**Deferred Tax:**

Deferred tax is recognized, subject to the consideration of prudence, on timing differences, being the difference between taxable incomes and accounting income that originate in one period and are capable of reversal in one or more subsequent periods. Deferred tax assets are not recognized on unabsorbed depreciation and carry forward of losses unless there is virtual certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized.

**Earnings per share:**

The basic earnings per share ("EPS") is computed by dividing the net profit after tax for the period attributable to equity shareholders by weighted average number of equity shares outstanding during the year.

For the purpose of calculating diluted earnings per share, the net profit after tax for the period attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares. The dilutive potential equity shares are deemed to be converted as of the beginning of the year, unless they have been issued at a later date.



**DR. N.R.K. BIO-TECH PRIVATE LIMITED**  
**NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2025**  
*(All amounts in Rs. hundreds, unless otherwise stated)*

**3 Share Capital**

Particulars	As at March 31st, 2025	As at March 31st, 2024
<b>Authorized Capital</b>		
<b>Equity Share Capital</b>		
50,00,000 number of equity shares of Rs. 10 each	5,00,000	5,00,000
<b>Total</b>	<b>5,00,000</b>	<b>5,00,000</b>
<b>Issued, Subscribed and Paid-up Capital</b>		
<b>Equity Share Capital</b>		
24,11,000 number of equity shares of Rs. 10 each fully paid up	2,41,100	2,41,100
<b>Total</b>	<b>2,41,100</b>	<b>2,41,100</b>

**(a) Equity Share Capital**

**(i) Reconciliation of Number of Equity Shares**

Particulars	As at March 31st, 2025		As at March 31st, 2024	
	Number	Amount	Number	Amount
<b>Issued, Subscribed and Paid-up Capital</b>				
Outstanding shares at the beginning of the year	24,110	2,41,100	2,500	25,000
Shares Issued during the year	-	-	21,610	2,16,100
Share bought back during the year	-	-	-	-
<b>Outstanding Shares at the end of the year</b>	<b>24,110</b>	<b>2,41,100</b>	<b>24,110</b>	<b>2,41,100</b>

**(ii) Details of Shareholders holding more than 5% of equity shares during the year**

Particulars	As at March 31st, 2025		As at March 31st, 2024	
	Number	Percentage %	Number	Percentage %
B Anand Kumar	2,41,100	10.00%	2,41,100	10.00%
JVRX Asset Management Pvt Ltd	3,61,650	15.00%	3,61,650	15.00%
K Venkata Nagabhushnam	2,41,100	10.00%	2,41,100	10.00%
K Venkata Narsimha Murty	2,41,100	10.00%	2,41,100	10.00%
K Vijay Bhaskar	2,41,100	10.00%	2,41,100	10.00%
Modi Properties Pvt Ltd	3,61,650	15.00%	6,02,750	25.00%
Modi Housing Pvt Ltd	2,41,100	10.00%	-	0.00%
N Kiran Kumar	2,41,100	10.00%	2,41,100	10.00%
N Krishna Veni	2,41,100	10.00%	2,41,100	10.00%
<b>Total</b>	<b>24,11,000</b>	<b>100.00%</b>	<b>24,11,000</b>	<b>100.00%</b>

**(iii) Rights, preference and restrictions attached to Equity Shares**

The Company has only one class of equity shares having a par value of ₹ 10 each per share. Each holder of equity shares is entitled to one vote per share. The dividend proposed by the Board of Directors is subject to the approval of the Shareholders in the ensuing Annual General Meeting.

**Note:** No dividends has been paid to Preference shareholders during the year.

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts if any. The distribution will be in proportion to number of equity shares held by the shareholders.

**4 Reserves and Surplus**

Particulars	As at March 31st, 2025	As at March 31st, 2024
<b>Securities Premium Account</b>		
Opening Balance	80,500	80,500
Add: Profit/(Loss) for the year		
<b>Closing Balance</b>	<b>80,500</b>	<b>80,500</b>
<b>Surplus/(Deficit) in Statement of Profit and Loss</b>		
Opening Balance	(3,75,862)	(2,99,015)
Add: Profit/(Loss) for the year	(1,23,160)	(76,847)
Closing Balance	(4,99,022)	(3,75,862)
<b>Total</b>	<b>(4,18,519)</b>	<b>(2,95,359)</b>



*[Handwritten signature]*



**DR. N.R.K. BIO-TECH PRIVATE LIMITED**  
**NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2025**  
*(All amounts in Rs. hundreds, unless otherwise stated)*

**5a Long- term Borrowings**

Particulars	As at March 31st, 2025	As at March 31st, 2024
<b>Secured:</b>		
Loan from Banks (Refer note (i) below)	-	-
Loan from Others (Refer note (i) below)	4,72,474	13,68,154
<b>Unsecured:</b>		
Loan from Banks (Refer note (i) below)	-	-
Loan from Others (Refer note (i) below)	32,27,166	19,36,434
<b>Total</b>	<b>36,99,640</b>	<b>33,04,588</b>

**5a Short- term Borrowings**

Particulars	As at March 31st, 2025	As at March 31st, 2024
<b>Secured:</b>		
Loan from Banks (Refer note (i) below)	625	76,050
Loan from Others (Refer note (i) below)	-	-
<b>Unsecured:</b>		
Loan from Banks (Refer note (i) below)	-	-
Loan from Others (Refer note (i) below)	-	-
<b>Total</b>	<b>625</b>	<b>76,050</b>

(i) Borrowing reported above includes:

Particulars	As at March 31st, 2025	As at March 31st, 2024
<b>Secured:</b>		
Bonds/Debentures	-	-
Term Loans		
from Banks	-	-
from Others	-	-
Deferred payment liabilities	-	-
Deposits	-	-
Loans and advances from related parties	-	-
Long term maturities of finance lease obligations	-	-
Other loans and advances		
Vehicle Loan	-	-
Other Loans	4,73,099	14,44,203
<b>Unsecured:</b>		
Bonds/Debentures	-	-
Term Loans		
from Banks	-	-
from Others	-	-
Deferred payment liabilities	-	-
Deposits	-	-
Loans and advances from related parties	20,00,915	8,35,183
Long term maturities of finance lease obligations	-	-
Other loans and advances	12,26,251	11,01,251
<b>Total</b>	<b>37,00,265</b>	<b>33,80,637</b>



*[Handwritten signature]*



*[Handwritten signature]*

DR. N.R.K. BIO-TECH PRIVATE LIMITED  
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2025  
(All amounts in Rs. hundreds, unless otherwise stated)

6 Trade Payables

Particulars	As at March 31st, 2025	As at March 31st, 2024
Sundry Creditors		
-Due to Micro, Small and Medium Enterprise*	19,642	-
-Due to Others	1,24,614	1,42,178
<b>Total</b>	<b>1,44,256</b>	<b>1,42,178</b>

\* The company does not have any information relating to amounts payable to Micro, Small and Medium Enterprise as on March 31, 2025

Note 6.1 Trade Payables Ageing Schedule

Trade Payable ageing schedule as on 31st March ,2025

PARTICULARS	Outstanding for the following periods from the due date of payment					
As at 31st March 2025	Not due	Less than 1 year	1-2 years	2-3 Years	More than 3 Years	Total
(i) Dues to MSME	-	19,642	-	-	-	19,642.09
(ii) Dues to Others	-	1,24,614	-	-	-	1,24,614
(iii) Disputed dues to MSME	-	-	-	-	-	-
(iv) Disputed dues to Others	-	-	-	-	-	-
<b>GRAND TOTAL</b>	<b>-</b>	<b>1,44,256</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>1,44,256</b>

Trade Payable ageing schedule as on 31st March ,2024

PARTICULARS	Outstanding for the following periods from the due date of payment					
As at 31st March 2024	Not due	Less than 1 year	1-2 years	2-3 Years	More than 3 Years	Total
(i) Dues to MSME	-	-	-	-	-	-
(ii) Dues to Others	-	1,42,178	-	-	-	1,42,178
(iii) Disputed dues to MSME	-	-	-	-	-	-
(iv) Disputed dues to Others	-	-	-	-	-	-
<b>GRAND TOTAL</b>	<b>-</b>	<b>1,42,178</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>1,42,178</b>





**DR. N.R.K. BIO-TECH PRIVATE LIMITED****NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2025***(All amounts in Rs. hundreds, unless otherwise stated)***7 Other Current Liabilities**

Particulars	As at March 31st, 2025	As at March 31st, 2024
TDS Payable	29,566	7,670
GST Payable	328	328
Professional Tax Payable	14	8
Provident Fund Payable	231	-
Deposits	10,000	10,000
Interest payable	1,55,712	32,429
Other payable	196	145
<b>Total</b>	<b>1,96,046</b>	<b>50,578</b>

**8 Short Term Provision**

Particulars	As at March 31st, 2025	As at March 31st, 2024
Provision for Audit Fees	369	350
Provision for ITR Filing fees	-	60
- TDS @ 10%	-	(41)
<b>Total</b>	<b>369</b>	<b>369</b>



Handwritten signature and initials (AV) in blue ink.

DR. N.R.K. BIO-TECH PRIVATE LIMITED  
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2025  
(All amounts in Rs. hundreds, unless otherwise stated)

9A Property, Plant & Equipment (Current Year, FY 2024-25)

Particulars	Gross Block			Depreciation				Net Block		
	As at April 1st, 2024	Additions	Adjustments	As at March 31st, 2025	As at April 1st, 2024	For the year	Adjustments	As at March 31st, 2025	As at March 31st, 2025	As at March 31st, 2024
<b>Tangible:</b>										
Land	1,58,425	-	-	1,58,425	-	-	-	-	1,58,425	1,58,425
Buildings	80,420	-	-	80,420	33,860	2,547	-	36,407	44,013	46,560
Motor Vehicle	6,999	-	-	6,999	4,138	985	-	5,123	1,876	2,861
Computers & Peripherals	299	-	-	299	53	95	-	147	152	247
<b>Total</b>	<b>2,46,144</b>	<b>-</b>	<b>-</b>	<b>2,46,144</b>	<b>38,051</b>	<b>3,626</b>	<b>-</b>	<b>41,677</b>	<b>2,04,466</b>	<b>2,08,093</b>

8A Property, Plant & Equipment (Current Year, FY 2023-24)

Particulars	Gross Block			Depreciation				Net Block		
	As at April 1st, 2023	Additions	Adjustments	As at March 31st, 2024	As at April 1st, 2023	For the year	Adjustments	As at March 31st, 2024	As at March 31st, 2024	As at March 31st, 2023
<b>Tangible:</b>										
Land	1,58,425	-	-	1,58,425	-	-	-	-	1,58,425	1,58,425
Buildings	80,420	-	-	80,420	31,314	2,547	-	33,860	46,560	49,107
Motor Vehicle	8,981	1,918	3,900	6,999	1,003	901	(2,234)	4,138	2,861	7,978
Computers & Peripherals	-	299	-	299	-	53	-	53	247	-
<b>Total</b>	<b>2,47,826</b>	<b>2,217</b>	<b>3,900</b>	<b>2,46,144</b>	<b>32,317</b>	<b>3,500</b>	<b>(2,234)</b>	<b>38,051</b>	<b>2,08,093</b>	<b>2,15,509</b>

9B Capital Work In Progress (Current Year, FY 2024-25)

Particulars	Gross Block			Depreciation				Net Block		
	As at April 1st, 2024	Additions	Adjustments	As at March 31st, 2025	As at April 1st, 2024	For the year	Adjustments	As at March 31st, 2025	As at March 31st, 2025	As at March 31st, 2024
Building under construction	28,55,307	3,80,451	-	32,35,759	-	-	-	-	32,35,759	28,55,307
<b>Total</b>	<b>28,55,307</b>	<b>3,80,451</b>	<b>-</b>	<b>32,35,759</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>32,35,759</b>	<b>28,55,307</b>

8B Capital Work In Progress (Current Year, FY 2023-24)

Particulars	Gross Block			Depreciation				Net Block		
	As at April 1st, 2023	Additions	Adjustments	As at March 31st, 2024	As at April 1st, 2023	For the year	Adjustments	As at March 31st, 2024	As at March 31st, 2024	As at March 31st, 2023
Building under construction	18,60,125	9,95,182	-	28,55,307	-	-	-	-	28,55,307	18,60,125
<b>Total</b>	<b>18,60,125</b>	<b>9,95,182</b>	<b>-</b>	<b>28,55,307</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>28,55,307</b>	<b>18,60,125</b>

CWIP Ageing Schedule-31st March 2025

Particulars	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 Years	2-3 Years	More than 3 Years	
Project in progress	3,80,452	9,95,182	11,60,562	6,99,563	32,35,759
<b>Total</b>	<b>3,80,452</b>	<b>9,95,182</b>	<b>11,60,562</b>	<b>6,99,563</b>	<b>32,35,759</b>

CWIP Ageing Schedule-31st March 2024

Particulars	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 Years	2-3 Years	More than 3 Years	
Project in progress	9,95,182	11,60,562	4,23,344	2,76,218	28,55,307
<b>Total</b>	<b>9,95,182</b>	<b>11,60,562</b>	<b>4,23,344</b>	<b>2,76,218</b>	<b>28,55,307</b>



*[Handwritten signature]*



DR. N.R.K. BIO-TECH PRIVATE LIMITED  
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2025  
(All amounts in Rs. hundreds, unless otherwise stated)

10 Deferred Tax Assets

Particulars	As at March 31st, 2025	As at March 31st, 2024
Deferred tax asset	5,939	35,795
<b>Total</b>	<b>5,939</b>	<b>35,795</b>

11 Trade receivables

Particulars	As at March 31st, 2025	As at March 31st, 2024
Sundry Debtors		
-Secured, Considered goods	-	-
-Unsecured, Considered goods	3,249	-
-Doubtful	-	-
<b>Total</b>	<b>3,249</b>	<b>-</b>

Note 11.1 Trade receivables Ageing Schedule

Trade receivables ageing schedule as on 31st March, 2025

PARTICULARS	Outstanding for the following periods from the due date of receipt					
As at 31st March 2025	Not due	Less than 1 year	1-2 years	2-3 Years	More than 3 Years	Total
(i) Secured, Considered goods	-	-	-	-	-	-
(ii) Unsecured, Considered goods	-	3,249	-	-	-	3,249
(iii) Doubtful	-	-	-	-	-	-
<b>GRAND TOTAL</b>	<b>-</b>	<b>3,249</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>3,249</b>

Trade receivables ageing schedule as on 31st March, 2024

PARTICULARS	Outstanding for the following periods from the due date of receipt					
As at 31st March 2024	Not due	Less than 1 year	1-2 years	2-3 Years	More than 3 Years	Total
(i) Secured, Considered goods	-	-	-	-	-	-
(ii) Unsecured, Considered goods	-	-	-	-	-	-
(iii) Doubtful	-	-	-	-	-	-
<b>GRAND TOTAL</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>

12 Cash and Cash Equivalents

Particulars	As at March 31st, 2025	As at March 31st, 2024
Cash-in-hand	1,145	1,207
Balance with Bank:		
In Term Deposits account	-	6,077
In Current account		
ICICI Bank	250	-
Yes Bank	2,637	1,328
<b>Total</b>	<b>4,032</b>	<b>8,613</b>



*[Handwritten signature]*

**DR. N.R.K. BIO-TECH PRIVATE LIMITED****NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2025***(All amounts in Rs. hundreds, unless otherwise stated)***13 Loans and Advances**

Particulars	As at March 31st, 2025	As at March 31st, 2024
<b>Secured:</b>		
Loans and Advances to Related Party	-	-
Loans and Advances to Others	80,033	85,840
<b>Unsecured:</b>		
Loans and Advances to Related Party	3,23,519	23,246
Loans and Advances to Others	6,519	5,729
<b>Total</b>	<b>4,10,071</b>	<b>1,14,815</b>

**(i) Borrowing reported above includes:**

Particulars	As at March 31st, 2025	As at March 31st, 2024
<b>Secured:</b>		
Bonds/Debentures	-	-
Loans and advances to Related Parties		
Deposits*	-	-
Loans and advances	-	-
Other loans and advances		
Deposits*	63,000	63,000
Loans and advances to suppliers	16,218	22,369
Others	815	471
<b>Unsecured:</b>		
Bonds/Debentures		-
Loans and advances to Related Parties		
Deposits*	2,560	3,000
Loans and advances	3,20,959	20,246
Other loans and advances		-
Deposits		-
Loans and advances to suppliers		-
Others	6,519	5,729
<b>Total</b>	<b>4,10,071</b>	<b>1,14,815</b>

\* Note: Secured loans and advances includes deposits

**14 Other Current Assets**

Particulars	As at March 31st, 2025	As at March 31st, 2024
Balance with Revenue Authorities	-	2,96,404
TDS Receivable	-	476.07
<b>Total</b>	<b>-</b>	<b>2,96,880</b>



AK



**DR. N.R.K. BIO-TECH PRIVATE LIMITED**  
**NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2025**  
(All amounts in Rs. hundreds, unless otherwise stated)

**15 Revenue from Operations**

Particulars	Year Ended March 31st, 2025	Year Ended March 31st, 2024
Sale of Goods	-	-
<b>Total</b>	-	-

**16 Other Income**

Particulars	Year Ended March 31st, 2025	Year Ended March 31st, 2024
Interest on Fixed Deposit	-	4,761
Miscellaneous Income	19,938	262
Interest on Income tax refund	21	30
<b>Total</b>	<b>19,960</b>	<b>5,052</b>

**17 Employee Benefit Expenses**

Particulars	Year Ended March 31st, 2025	Year Ended March 31st, 2024
Salary, wages, other remuneration	25,262	7,346
Staff Welfare Expenses	709	4
<b>Total</b>	<b>25,971</b>	<b>7,350</b>

**18 Finance Cost**

Particulars	Year Ended March 31st, 2025	Year Ended March 31st, 2024
Bank Charges	7	28
<b>Total</b>	<b>7</b>	<b>28</b>

**18 Other Administrative Expenses**

Particulars	Year Ended March 31st, 2025	Year Ended March 31st, 2024
Audit fee	410	410
Consultancy Charges	71,435	13,050
Written Off	-	719
Admin Service Charges	509	7,015
Carhire Charges	-	1,683
Maintenance Charges	4,263	39,184
ROC Charges	68	2,250
GST Late Fees	-	7
Interest on TDS	479	506
Other miscellaneous expenses	5,960	2,739
Printing & Stationery	429	847
Advertisement & Promotion Expenses	106	328
Loss on sale of Car	-	2,234
<b>Total</b>	<b>83,660</b>	<b>70,971</b>



AK

**DR. N.R.K. BIO-TECH PRIVATE LIMITED**  
**NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2025**  
(All amounts in Rs. hundreds, unless otherwise stated)

- 19 Provisions, Contingent Liability and Contingent Asset  
The company has capital commitments as mentioned below:

**(A) Capital commitment:-**

Particulars	Year Ended March 31st, 2025
Estimated amount of construction remaining to be executed	18,19,549
Loan repayment to Aditya Birla Finance Limited	9,44,000
<b>Total Commitment</b>	<b>27,63,549</b>

Project Construction estimated to be completed by 31st December, 2025.

20 **Earnings Per Share**

Earnings Per Share	Year Ended March 31st, 2025	Year Ended March 31st, 2024
Profit/(Loss) considered for computation of EPS	(92,845)	(76,798)
Shares:		
Number of equity shares at the beginning of period	24,11,000	2,50,000
Add: Shares issued during the year	-	21,61,000
Total number of equity shares outstanding	24,11,000	24,11,000
Weighted Average number of equity shares	24,11,000	24,11,000
<b>Basic Earning Per Share (EPS)</b>	<b>(3.85)</b>	<b>(3.19)</b>
Profit/(Loss) considered for computation of DPS	(92,845)	(76,798)
Shares:		
Number of equity shares at the beginning of period	24,11,000	2,50,000
Add: Shares issued during the year	-	21,61,000
Total number of equity shares outstanding	24,11,000	24,11,000
Weighted Average number of equity shares	24,11,000	20,50,833
Number of Non-Cumulative CCPS at the beginning of period	-	-
Add: Shares issued during the year	-	-
Total number of CCPS outstanding	-	-
<b>Diluted Earning Per Share (DPS)</b>	<b>(4)</b>	<b>(4)</b>

21 Deferred Tax Asset/(Liability) (Net)	Year Ended March 31st, 2025	Year Ended March 31st, 2024
A. Deferred Tax Liability	-	-
B. Deferred Tax Asset	36,255	35,795
<b>Net Deferred Tax Asset/(Deferred Tax Liability)</b>	<b>36,255</b>	<b>35,795</b>

22 **Related Party Disclosure (AS 18)**

- (a) **Name of the related parties and nature of relationship (as per AS 18)**

**Name of Related Party**  
Anand Kumar Bhashyakarla  
Milind Ravi  
Soham Satish Modi

**Nature of Relationship**  
Director  
Director  
Director



*[Handwritten signature]*



(b) Transactions with Related Parties

Name of Related Party	Nature	Year Ended March 31st, 2025	Year Ended March 31st, 2024
Anand Kumar Bhashyakarla	Loan Repayment	40,000	31,053
JVRX Asset Management Pvt Ltd	Interest Payable	6,331	6,064
JVRX Asset Management Pvt Ltd	Loan Repayment	-	24,110
JVRX Asset Management Pvt Ltd	Issued Equity	-	-
Kalluri Venkata Nagabushnam	Shares	-	24,110
Kalluri Venkata Narasimha Murthy	Loan Taken	-	40,000
Modi Properties Pvt Ltd	Loan Taken	55,000	15,000
Modi Properties Pvt Ltd	Loan Taken	11,72,913	2,84,970
Modi Properties Pvt Ltd	Loan Repayment	5,32,573	69,250
Modi Properties Pvt Ltd	Interest Payable	78,703	24,078
Modi Properties Pvt Ltd	Issued Equity	-	-
Modi Properties Pvt Ltd	Shares	(24,110)	24,110
Modi Housing Pvt Ltd	Issued Equity	-	-
Nareddy Kiran Kumar Reddy	Shares	24,110	-
Naredla Krishnaveni	Loan Taken	50,000	20,000
Naredla Krishnaveni	Loan Taken	-	70,000
Vijaya Bhaskar Reddy	Loan Repayment	10,000	-
Modi Constructions & Realtors LLP	Unsecured Loan	30,000	10,000
Modi Constructions & Realtors LLP	Loans & Advances (Assets)	200	71,883
Modi Constructions & Realtors LLP	Loans & Advances (Assets)	(20,546)	20,100
Modi Housing Pvt Ltd	Loans & Advances (Assets)	-	-
Summit Builders	Loan Taken	13,093	-
Summit Builders	Service Provider	-	-

(c) Related Parties Balances

Name of Related Party	Nature of Relationship	Year Ended March 31st, 2025	Year Ended March 31st, 2024
Anand Kumar Bhashyakarla	Unsecured Loan	2,71,250	2,31,250
JVRX Asset Management Pvt Ltd	Unsecured Loan	66,511	66,511
Kalluri Venkata Nagabushnam	Unsecured Loan	2,31,250	2,31,250
Kalluri Venkata Narasimha Murthy	Unsecured Loan	2,86,250	2,31,250
Modi Properties Pvt Ltd	Unsecured Loan	11,31,155	5,12,422
Modi Housing Pvt Ltd	Unsecured Loan	5,07,000	-
Nareddy Kiran Kumar Reddy	Unsecured Loan	2,81,250	2,31,250
Naredla Krishnaveni	Unsecured Loan	1,66,250	1,76,250
Vijaya Bhaskar Reddy	Unsecured Loan	2,61,251	2,31,251
Modi Properties Pvt Ltd	Capital Account	36,165	60,27,500
Modi Housing Pvt Ltd	Capital Account	24,110	-
Modi Housing Pvt Ltd	Loans & Advances	9,640	-
Modi Constructions & Realtors LLP	Loans & Advances	200	20,24,578

23 Previous years' figures have been regrouped/ reclassified wherever necessary in the current year's grouping/ classification.

24 No transactions to report against the following:

- Crypto Currency or Virtual Currency.
- Benami Property held under Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.
- Registration of charges or satisfaction with Registrar of Companies.
- Relating to borrowed funds:
  - Wilful defaulter.
  - Utilisation of borrowed funds & share premium.
  - Borrowings obtained on the basis of security of current assets.
  - Discrepancy in utilisation of borrowings.

25 The Company is currently in its pre-operative phase and is in the process of setting up its Bio-tech leasing facility. As at March 31, 2025, the Company has incurred substantial expenditure on Capital Work in Progress amounting to Rs. 32,35,759 (amount in hundreds) which is reflected under Non-Current Assets. These expenditures primarily comprise major components like construction costs, pre-operative expenses etc. Due to the pre-operative nature of activities and absence of commercial operations, the Company has accumulated losses resulting in negative net assets of Rs. 1,47,104 (amount in hundreds). The management is confident of commencing commercial operations by 31st December, 2025 and has secured necessary funding commitments from Promoters and Financers to meet the project completion costs and working capital requirements. Accordingly, these financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.



SM



AK

**DR. N.R.K. BIO-TECH PRIVATE LIMITED**  
**NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2025**  
*(All amounts in Rs. hundreds, unless otherwise stated)*

**26 Ratios**

Sl. No	Particulars	Numerator	Denominator	March 31, 2025	March 31, 2024	Variance	Reason for Variance
(i)	Current Ratio	Current assets	Current liabilities	1.22	1.56	0.22	Company has obliged to pay loan instalments which is to be accrued during the assessment year.
(ii)	Debt-Equity Ratio	Total Debt	Shareholder's Equity	-20.85	-60.90	0.66	CCPS some Other loans converted into Equity shares.
(iii)	Debt Service Coverage Ratio	Earnings available for debt service	Debt Service	NA	NA	NA	The company has not started its operations till 31.03.2024
(iv)	Return on Equity (ROE)	Net Profits after taxes	Average Shareholder's Equity	NA	NA	NA	The company has not started its operations till 31.03.2024
(v)	Inventory turnover ratio	Cost of Goods Sold	Average Inventory	NA	NA	NA	The company has not started its operations till 31.03.2024
(vi)	Trade Receivable turnover ratio	Revenue	Average Trade Receivable	NA	NA	NA	The company has not started its operations till 31.03.2024
(vii)	Trade payables turnover ratio	Purchases of services and other expenses	Average Trade Payables	NA	NA	NA	The company has not started its operations till 31.03.2024
(viii)	Net Capital Turnover Ratio	Revenue	Working Capital	NA	NA	NA	The company has not started its operations till 31.03.2024
(ix)	Net profit ratio	Net Profit	Revenue	NA	NA	NA	The company has not started its operations till 31.03.2024
(x)	Return on capital employed (ROCE)	Earning before interest and taxes	Capital Employed	NA	NA	NA	The company has not started its operations till 31.03.2024
(xi)	Return on Investment (ROI)	Income generated from investments	Time weighted Average Investments	NA	NA	NA	The company has not started its operations till 31.03.2024

As per out report of even date  
for Laxminivas & Co.  
**Chartered Accountants**  
Firm Registration No. 0111685

For and on behalf of directors of  
**Dr. N.R.K. Bio-Tech Private Limited**  
CIN: U45100TG2004PTC044950



**Vijay Singh**  
Partner  
Membership No. 231671

Place : Hyderabad

Date : 02 September 2025

**Soham Sush Modi**  
Director  
DIN: 00522546

**Anand Kumar Bhashyakarla**  
Director  
DIN: 07739186





Date: 18<sup>th</sup> September, 2025

To,  
Board of Directors,  
Dr NRK Biotech Private Limited,  
H.No. 8-2-268/1/A/1/B&C,  
2nd Floor, Tulasi Homes,  
Road No.3 Banjara Hills  
Hyderabad, Telangana-500034

Dear Sir,

### Objective and scope of the audit

We refer to your communication regarding our reappointment as the statutory auditors of the Company. You have requested that we audit the financial statements of the Company, as defined under Section 2(40) of the Companies Act, 2013, for the financial year beginning 1st April 2024 and ending 31st March 2025.

We are pleased to confirm our acceptance and our understanding of this audit engagement by means of this letter. Our audit will be conducted with the objective of expressing an opinion if the aforesaid financial statements give the information required by the 2013 Act in the manners so required, and give a true and fair view in conformity with the applicable accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2025, and its profit/loss and its cash flows for the year ended on that date which, inter alia, includes reporting in conjunction whether the Company has an adequate internal financial control system over financial reporting in place and the operating effectiveness of such controls.

Further, the objectives of our audit are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Standards on Auditing (SAs) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

### Audit Responsibility and Limitations

We will conduct our audit in accordance with the Standards on Auditing (SAs), specified under Section 143(10) of the 2013 Act. Those Standards require that we comply with ethical requirements. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion.



T: 040 2324 0700  
040 2324 0900



[www.Lncofirm.in](http://www.Lncofirm.in)



**Laxminiwas & Co.**

Head Office: 6-3-569, 4<sup>th</sup> Floor, Above BMW Showroom,  
Opp. RTA Office Khairatabad, Hyderabad 500082, Telangana, India.

BENGALURU | MYSORE | VIZAG | CHENNAI | MUMBAI | DELHI | DUBAI

We Keep It Simple We Make It Work

The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Because of the inherent limitations of an audit, including the possibility of collusion or improper management override of controls, there is an unavoidable risk that material misstatements due to fraud or error may occur and not be detected, even though the audit is properly planned and performed in accordance with the SAs. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In making our risk assessments, we consider internal control relevant to the entity's preparation of the financial statements in order to design audit procedures that are appropriate in the circumstances expressing an opinion on the effectiveness of the entity's internal control.

### **Management's Responsibilities and Representations**

Our audit will be conducted on the basis that management acknowledges and understands that they have responsibility:

- (a) For the preparation of financial statements that give a true and fair view in accordance with the Financial Reporting Standards and other generally accepted accounting principles in India. This includes:

- Compliance with the applicable provisions of the 2013 Act
- Proper maintenance of accounts and other matters connected therewith;
- The responsibility for the preparation of financial statements on a going concern basis.
- The responsibility for selection and consistent application of appropriate accounting policies, including implementation of applicable accounting standards along with proper





- explanation relating to any material departures from those accounting standards.
  - The responsibility for making judgments and estimates those are reasonable and prudent so as to give a true and fair view of the state of affairs of the entity at the end of the financial year and of the profit or loss of the entity for that period.
  - Taking proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the 2013 Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
  - Devising proper systems to ensure compliance with the provisions of all applicable laws and that such system were adequate and operating effectively.
- (b) Identifying and informing us of financial transactions or matters that may have any adverse effect on the functioning of the Company.
- (c) Identifying and informing us of:
- All the pending litigations and confirming that the impact of the pending litigations on the Company's financial position has been disclosed in its financial statements;
  - All material foreseeable losses, if any, on long term contracts including derivative contracts and the accrual for such losses as required under any law or accounting standards; and
  - Any delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.
- (d) Informing us of facts that may affect the financial statements, of which Management may become aware during the period from the date of our report to the date the financial statements are issued.
- (e) Identifying and informing us as to whether any director is disqualified as on March 31, 2025 from being appointed as a director in terms of Section 164(2) of the 2013 Act. This should be supported by written representations received from the directors as on March 31, 2025 and taken on record by the Board of Directors.
- (f) To provide us with:
- Access, at all times, to all information, including the books, account, vouchers and other records and documentation, of the Company, whether kept at the head office of the company or elsewhere, of which management is aware that is relevant to the preparation of the financial statements such as records, documentation and other matters. This will include books of account maintained in electronic mode;
  - Access, at all times, to the records of all the subsidiaries (including associate companies and joint ventures as per Explanation to Section 129(3) of the 2013 Act of the Company in so far as it relates to the consolidation of its financial statements, as envisaged in the 2013 Act;
  - Access to reports, if any, relating to internal reporting on frauds (e.g., vigil mechanism reports etc.), including those submitted by cost accountant or company secretary in practice to the extent it relates to their reporting on frauds in accordance with the requirements of Section 143(12) of the 2013 Act;
  - Additional information that we may request from management for the purpose of the audit; and
  - Unrestricted access to persons within the entity from whom we determine it necessary to obtain audit evidence. This includes our entitlement to require from the officers of the Company such information and explanations as we may think necessary for the performance of our duties as auditor.
  - All the required support to discharge our duties as the statutory auditors as stipulated



under the Companies Act, 2013/ ICAI standards on auditing and applicable guidance.

As part of our audit process, we will request from the Management written confirmation concerning representations made to us in connection with our audit.

Our report prepared in accordance with relevant provisions of the 2013 Act would be addressed to the shareholders of the Company for adoption of the accounts at the Annual General Meeting. In respect of other services, our report would be addressed to the Board of Directors. The form and content of our report may need to be amended in the light of our audit findings.

In accordance with the requirements of Section 143(12) of the 2013 Act, if in the course of performance of our duties as auditor, we have reason to believe that an offence involving fraud is being or has been committed against the Company by officers or employees of the Company, we will be required to report to the Central Government, in accordance with the rules prescribed in this regard which, *inter alia*, requires us to forward our report to the Board or Audit Committee, as the case may be, seeking their reply or observations, to enable us to forward the same to the Central Government.

As stated above, given that we are required as per Section 143(12) of the Act to report on frauds, such reporting will be made in good faith and, therefore, cannot be considered as breach of maintenance of client confidentiality requirements or be subject to any suit, prosecution or other legal proceeding since it is done in pursuance of the 2013 Act or of any rules or orders made thereunder.

We may involve specialists and staff from our affiliated network firms to perform certain specific audit procedures during the course of our audit.

In terms of Standard on Auditing 720 - "The Auditor's Responsibility in Relation to Other Information in Documents Containing Audited Financial Statements" issued by the ICAI and deemed to be prescribed by the Central Government in accordance with Section 143(10) of the 2013 Act, we request you to provide to us a Draft of the Annual Report containing the audited financial statements so as to enable us to read the same and communicate material inconsistencies, if any, with the audited financial statements, before issuing the auditor's report on the financial statements.

As part of our audit process, we will request from management, written confirmation concerning representations made to us in connection with the audit.

#### **Ownership of and access to our working papers**

The working papers prepared in conjunction with our audits are the property of our Firm, constitute confidential information and will be retained by us in accordance with our Firm's policies and procedures. However, we hereby acknowledge that the details or data received from you for preparation of these working papers are confidential information of the company and will not be disclosed by us to any third party, except as set out in paragraph below or when required by legislation, without the prior written consent from the company.

We also wish to invite your attention to the fact that our audit process is subject to '**peer review**' under the Chartered Accountants Act, 1949 to be conducted by an independent reviewer. The reviewer may inspect, examine or take abstract of our working papers during the course of the peer review.

Neither party shall have any confidentiality obligations with respect to any information that is





disclosed pursuant to applicable law, regulation, subpoena, other legal process or professional obligations or in connection with the enforcement of the recipient's rights under this Agreement.

### **Fees**

Our fees is computed on the basis of the time spent on the Company's affairs by the partners and our staff and on the levels of skill and responsibility involved. The fee for the services described is proposed to be Rs. 41,000 (Rupees Forty one Thousand Only) and payable on annual basis subject to the terms and conditions above. Out-of-pocket expenses, including transportation, accommodation, telecommunications, postage, copying and printing expenses our bills are payable promptly on presentation. Out of expenses will be payable on actual basis.

In the event that, due to unforeseeable reasons, the actual time spent on these services under this engagement letter is substantially less or more than expected at the time of signing this engagement letter, the company and Laxminiwas & Co will negotiate and mutually revise the fee under this engagement letter. Such revision will be set out in writing by way of "Amendment to Engagement Letter".

### **Agreement of terms and communications**

Please sign and return the attached copy of this letter to indicate your acknowledgement of, and agreement with, the arrangements for our audit of the financial statements including our respective responsibilities.

If the Company has questions or concerns about our services, the Company may contact Mr. Dayaniwas Sharma, the Partner responsible for the quality of our service to the Company.


If the Company requires any further information, or wish to discuss the terms of our engagement further before replying, please do not hesitate to contact Mr. Vijay Singh, lead engagement partner.

Yours faithfully,

For **Laxminiwas & Co.,**  
Chartered Accountants

  
**Vijay Singh**  
Partner

Membership No: 221671



The terms of this engagement are accepted by SOHAN MODI on behalf of Dr NRK Biotech Private Limited who represents that he/she is authorized to accept these terms on behalf of the company.

For Dr NRK Biotech Private Limited

Name: SOHAN MODI

Designation: DIRECTOR

Place: Hyderabad

A handwritten signature in black ink, appearing to read 'Sohan', with a long horizontal stroke extending to the right.